12:00 AM
Oct 15, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

PV-10: Phase I expanded

Provectus expanded an open-label, dose-escalation, U.S. Phase I trial evaluating single injections of 0.25 and 0.5 mL PV-10 per mL lesion volume in up to 6 patients with cancer metastasized to the liver or with recurrent HCC to...

Read the full 169 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >